explore -WSS

explore

author：comprehensive 2025-08-14 20:06:24 - browse：329

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Sen. Bill Cassidy on how to lower drug prices

focus

WSS

Another man arrested in connection with shooting at Kansas nightclub

Another man arrested in connection with shooting at Kansas nightclub

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Bird flu makes raw milk dangerous to consume, mouse study finds

What to know about a major upcoming Wegovy heart health study

Decentralized clinical trials need collaboration to achieve wider use

focus

explore

leisure time

23andMe had bad news about my health. I wish a person had delivered it

House panel to mark up pandemic

Trump demands the U.S. pay no more for drugs than other countries … again

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

In Memoriam: Notable people who died in 2023

The Bio Revolution is changing business and society

In Memoriam: Notable people who died in 2023

Congress: Prevent baby formula shortages by passing a new bill

In Memoriam: Notable people who died in 2023

Stroke rates rising, especially in working

hotspot

US intelligence assessment says Iran not currently developing nuclear weapons

The world needs the new pandemic treaty

Pharma’s losing bet in New Jersey

Decentralized clinical trials need collaboration to achieve wider use

Stroke rates rising, especially in working

Congress: Prevent baby formula shortages by passing a new bill

focus

focus

focus

hotspot